Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results
09. November 2015 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2015.
Financial...
Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism
29. Oktober 2015 15:12 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the Division of Bone, Reproductive and Urologic Products of the U.S. Food and...
Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results
10. August 2015 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2015.
Financial Results...
Repros Announces Date of FDA Advisory Committee Review of NDA
08. Juni 2015 17:48 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, June 8, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the Division of Bone, Reproductive and Urologic Products of the U.S. Food and...
Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results
07. Mai 2015 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, May 7, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2015.
Financial Results...
Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application
15. April 2015 16:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, April 15, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User...
Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance
06. April 2015 16:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, April 6, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the European Medicines Agency (EMA) has informed the Company, through Repros'...
Repros Announces Acceptance for Filing of NDA
01. April 2015 16:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, April 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the New Drug Application (NDA) for its enclomiphene citrate product candidate,...
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results
16. März 2015 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, March 16, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31,...
Repros Submits New Drug Application to FDA for Androxal (R)
02. Februar 2015 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported that it has electronically submitted a New Drug Application (NDA) to the U.S. Food...